Sarcomatrix Therapeutics
Sarcomatrix Therapeutics, with a valuation of $14.3 million, is raising funds on PicMii. The company is working to unveil novel therapeutics for the treatment of Duchenne Muscular Dystrophy. Sarcomatrix Therapeutics aims to target the root causes of neuromuscular disorders and is gearing up for first-in-human clinical trials for its products S-969 and LAM-111. The business works on a partnership-based business model and will outsource clinical trials and manufacturing to renowned partners in the field. David Craig, David Alan Maine, Dean Burkin, and Ryan Wuebbles founded Sarcomatrix Therapeutics in May 2022. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1.2 million. The campaign proceeds will be used for research and development, inventory, company employment, and working capital.
Investment Overview
Raised: $500
Deal Terms
Total Commitments ($USD)
- Platform
- PicMii
- Start Date
- 10/29/2024
- Close Date
- 01/31/2025
$10,000
$1,175,000
$500
Equity - Common
Seed
RegCF
$2.50
$13,125,000
Company & Team
Company
- Year Founded
- 2022
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $177,875
- Grants
- $8,000,000
- VC Backed?
- No
Growth Charts
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Valuation History
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.